No Data
Exact Sciences: Maintaining Market Dominance With Cologuard Amid Emerging Competition
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening With Multiple Data Presentations at DDW 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies a
LabCorp Partner Geneoscopy Wins FDA Approval of Colorectal Cancer Test ColoSense
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Earnings reports and a dovish stance from the Federal Reserve lifted stocks last week. Major indices reacted positively, particularly to earnings from high-profile companies that hold significant weig
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
There's No Escaping Exact Sciences Corporation's (NASDAQ:EXAS) Muted Revenues
With a price-to-sales (or "P/S") ratio of 4.4x Exact Sciences Corporation (NASDAQ:EXAS) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the U